145 related articles for article (PubMed ID: 38414420)
1. Real-world evidence of Pressure-Enabled Drug Delivery for trans-arterial chemoembolization and radioembolization among patients with hepatocellular carcinoma and liver metastases.
Cook K; Gupta D; Liu Y; Miller-Rosales C; Wei F; Tuttle E; Katz SC; Marshak R; Kim AY
Curr Med Res Opin; 2024 Apr; 40(4):591-598. PubMed ID: 38414420
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study.
Kwon JH; Kim GM; Han K; Won JY; Kim MD; Lee DY; Lee J; Choi W; Kim YS; Kim DY; Han KH
Cardiovasc Intervent Radiol; 2018 Mar; 41(3):459-465. PubMed ID: 29067511
[TBL] [Abstract][Full Text] [Related]
3. Unresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis.
Lobo L; Yakoub D; Picado O; Ripat C; Pendola F; Sharma R; ElTawil R; Kwon D; Venkat S; Portelance L; Yechieli R
Cardiovasc Intervent Radiol; 2016 Nov; 39(11):1580-1588. PubMed ID: 27586657
[TBL] [Abstract][Full Text] [Related]
4. Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality.
Kim DY; Han KH
Hepatol Int; 2016 Nov; 10(6):883-892. PubMed ID: 27126821
[TBL] [Abstract][Full Text] [Related]
5. Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis.
Patel MV; Davies H; Williams AO; Bromilow T; Baker H; Mealing S; Holmes H; Anderson N; Ahmed O
J Med Econ; 2023; 26(1):1061-1071. PubMed ID: 37632520
[TBL] [Abstract][Full Text] [Related]
6. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization.
Lewandowski RJ; Kulik LM; Riaz A; Senthilnathan S; Mulcahy MF; Ryu RK; Ibrahim SM; Sato KT; Baker T; Miller FH; Omary R; Abecassis M; Salem R
Am J Transplant; 2009 Aug; 9(8):1920-8. PubMed ID: 19552767
[TBL] [Abstract][Full Text] [Related]
7. Transarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
Song JE; Jung KS; Kim DY; Song K; Won JY; Lee HW; Kim BK; Kim SU; Park JY; Ahn SH; Seong J; Han KH
Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):396-406. PubMed ID: 28871990
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma.
Moreno-Luna LE; Yang JD; Sanchez W; Paz-Fumagalli R; Harnois DM; Mettler TA; Gansen DN; de Groen PC; Lazaridis KN; Narayanan Menon KV; Larusso NF; Alberts SR; Gores GJ; Fleming CJ; Slettedahl SW; Harmsen WS; Therneau TM; Wiseman GA; Andrews JC; Roberts LR
Cardiovasc Intervent Radiol; 2013 Jun; 36(3):714-23. PubMed ID: 23093355
[TBL] [Abstract][Full Text] [Related]
9. Comparison of health-related quality of life after transarterial chemoembolization and transarterial radioembolization in patients with unresectable hepatocellular carcinoma.
Kirchner T; Marquardt S; Werncke T; Kirstein MM; Brunkhorst T; Wacker F; Vogel A; Rodt T
Abdom Radiol (NY); 2019 Apr; 44(4):1554-1561. PubMed ID: 30311050
[TBL] [Abstract][Full Text] [Related]
10. The position of transarterial chemoembolization with drug-eluting beads and yttrium-90 transarterial radioembolization in patients with hepatocellular carcinoma: Consensus statements from a Delphi-method expert panel in Turkey.
Akarca US; Akhan O; Bilgiç S; Bozkurt MF; Cantaşdemir M; Çermik TF; Çakaloğlu Y; Er Ö; Ilgıt E; Çapa Kaya G; Küçük NÖ; Numan F; Parıldar M; Türkmen C
Diagn Interv Radiol; 2021 Nov; 27(6):732-739. PubMed ID: 34792027
[TBL] [Abstract][Full Text] [Related]
11. Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion.
Spreafico C; Sposito C; Vaiani M; Cascella T; Bhoori S; Morosi C; Lanocita R; Romito R; Chiesa C; Maccauro M; Marchianò A; Mazzaferro V
J Hepatol; 2018 Apr; 68(4):724-732. PubMed ID: 29331342
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Liver Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma After Segmental Transarterial Radioembolization.
Hardy-Abeloos C; Lazarev S; Ru M; Kim E; Fischman A; Moshier E; Rosenzweig K; Buckstein M
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):968-976. PubMed ID: 31536781
[TBL] [Abstract][Full Text] [Related]
13. Clinical Application of Trans-Arterial Radioembolization in Hepatic Malignancies in Europe: First Results from the Prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT).
Helmberger T; Golfieri R; Pech M; Pfammatter T; Arnold D; Cianni R; Maleux G; Munneke G; Pellerin O; Peynircioglu B; Sangro B; Schaefer N; de Jong N; Bilbao JI; ;
Cardiovasc Intervent Radiol; 2021 Jan; 44(1):21-35. PubMed ID: 32959085
[TBL] [Abstract][Full Text] [Related]
14. Radioembolization for the treatment of hepatocellular carcinoma.
Kim HC
Clin Mol Hepatol; 2017 Jun; 23(2):109-114. PubMed ID: 28494530
[TBL] [Abstract][Full Text] [Related]
15. Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma.
Kallini JR; Gabr A; Salem R; Lewandowski RJ
Adv Ther; 2016 May; 33(5):699-714. PubMed ID: 27039186
[TBL] [Abstract][Full Text] [Related]
16. Transarterial Radioembolization versus Transarterial Chemoembolization Plus Percutaneous Ablation for Unresectable, Solitary Hepatocellular Carcinoma of ≥3 cm: A Propensity Score-Matched Study.
Yu Q; Thapa N; Karani K; Navuluri R; Ahmed O; Van Ha T
J Vasc Interv Radiol; 2022 Dec; 33(12):1570-1577.e1. PubMed ID: 36100064
[TBL] [Abstract][Full Text] [Related]
17. Quantification of Blood Pressure Changes in the Vascular Compartment When Using an Anti-Reflux Catheter during Chemoembolization versus Radioembolization: A Retrospective Case Series.
Rose SC; Narsinh KH; Newton IG
J Vasc Interv Radiol; 2017 Jan; 28(1):103-110. PubMed ID: 27840042
[TBL] [Abstract][Full Text] [Related]
18. In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?
El Fouly A; Ertle J; El Dorry A; Shaker MK; Dechêne A; Abdella H; Mueller S; Barakat E; Lauenstein T; Bockisch A; Gerken G; Schlaak JF
Liver Int; 2015 Feb; 35(2):627-35. PubMed ID: 25040497
[TBL] [Abstract][Full Text] [Related]
19. Transarterial Chemoembolization vs Radioembolization for Neuroendocrine Liver Metastases: A Multi-Institutional Analysis.
Egger ME; Armstrong E; Martin RC; Scoggins CR; Philips P; Shah M; Konda B; Dillhoff M; Pawlik TM; Cloyd JM
J Am Coll Surg; 2020 Apr; 230(4):363-370. PubMed ID: 32032719
[TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of Transarterial Radioembolisation in Patients with Intermediate or Advanced Stage Hepatocellular Carcinoma Refractory to Chemoembolisation.
Klompenhouwer EG; Dresen RC; Verslype C; Laenen A; De Hertogh G; Deroose CM; Bonne L; Vandevaveye V; Maleux G
Cardiovasc Intervent Radiol; 2017 Dec; 40(12):1882-1890. PubMed ID: 28685382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]